| |
DVTa
|
PEa
|
OTEa
|
|---|
|
N/P-Yb
|
Rate/1,000c (95% CI)
|
N/P-Yb
|
Rate/1,000c (95% CI)
|
N/P-Yb
|
Rate/1,000c (95% CI)
|
|---|
|
By major STS subtype
|
|
Angiosarcoma (n = 184)
|
14/147
|
95.4 (52.1, 160.0)
|
<11
|
26.5 (7.2, 68.0)
|
<11
|
39.8 (14.6, 86.6)
|
|
Fibrosarcoma (n = 64)
|
<11
|
72.1 (19.6, 184.5)
|
0
|
0
|
<11
|
17.6 (0.4, 97.8)
|
|
GIST (n = 845)
|
94/683
|
137.6 (111.2, 168.4)
|
33/721
|
45.7 (31.5, 64.2)
|
23/730
|
31.5 (20.0, 47.3)
|
|
Leiomyosarcoma (n = 264)
|
19/210
|
90.6 (54.5, 141.4)
|
<11
|
28.0 (10.3, 60.8)
|
<11
|
32.6 (13.1, 67.1)
|
|
Liposarcoma (n = 224)
|
13/118
|
110.1 (58.6, 188.2)
|
<11
|
24.5 (5.1, 71.7)
|
<11
|
24.5 (5.0, 71.5)
|
|
MFH (n = 184)
|
20/178
|
112.2 (68.5, 173.3)
|
<11
|
21.9 (6.0, 55.9)
|
<11
|
27.3 (8.9, 63.6)
|
|
Nerve sheath tumor (n = 118)
|
15/93
|
160.8 (90.0, 265.3)
|
<11
|
40.7 (11.1, 104.2)
|
<11
|
49.8 (16.2, 116.3)
|
|
Sarcoma, NOS (n = 1,422)
|
166/812
|
204.4 (174.5, 237.9)
|
41/862
|
47.5 (34.1, 64.5)
|
41/858
|
47.8 (34.3, 64.8)
|
|
By history of VTEe
|
|
Yes
|
61/51
|
1199.2 (917.3–1540.5)
|
11/14
|
785.5 (392.3–1406.0)
|
30/50
|
599.2 (404.3–855.4)
|
|
No
|
306/2,417
|
126.6 (112.8–141.6)
|
94/2,575
|
27.6 (24.3–31.1)
|
76/2,540
|
29.9 (23.6–37.5)
|
|
Rate ratio (yes vs. no)d
|
–
|
9.5 (7.2–12.5)
|
–
|
21.5 (11.5–40.2)
|
–
|
20.0 (13.1–30.6)
|
|
By history of CVD eventf
|
|
Yes
|
120/579
|
207.3 (171.9–247.9)
|
29/623
|
46.6 (31.2–66.9)
|
39/619
|
63.1 (44.8–86.2)
|
|
No
|
247/1,889
|
130.8 (115.0–148.1)
|
76/1,966
|
38.7 (30.5–48.4)
|
67/1,971
|
34.0 (26.3–43.2)
|
|
Rate ratio (yes vs. no)d
|
–
|
1.6 (1.3–2.0)
| |
1.2 (0.8–1.8)
| |
1.9 (1.3–2.8)
|
|
By disease stage
|
|
Localized
|
133/1,236
|
107.6 (90.1–127.5)
|
38/1,290
|
29.5 (20.9–40.4)
|
34/1,295
|
26.3 (18.2–36.7)
|
|
Regional
|
93/586
|
158.7 (128.1–194.4)
|
26/614
|
42.3 (27.7–62.1)
|
34/610
|
55.7 (38.6–77.9)
|
|
Distant
|
86/380
|
238.9 (191.1–295.0)
|
25/385
|
65.0 (42.1–95.9)
|
19/387
|
49.1 (29.6–76.7)
|
|
Rate ratio (regional and distant. vs. local)d
|
–
|
1.5 (1.1–1.9)
|
–
|
1.4 (0.9–2.4)
|
–
|
2.1 (1.3–3.4)
|
|
By chemotherapy
|
|
Yes
|
74/324
|
227.9 (178.9–286.1)
|
20/348
|
57.5 (35.1–88.7)
|
19/346
|
54.9 (33.0–85.7)
|
|
No
|
293/2,413
|
136.7 (121.5–153.3)
|
85/2,241
|
37.9 (30.3–46.9)
|
87/2,244
|
38.8 (31.1–47.8)
|
|
Rate ratio (yes vs. no)d
|
–
|
1.7 (1.3–2.2)
|
–
|
1.5 (0.9–2.5)
| |
1.4 (0.9–2.3)
|
|
By surgery of primary tumor
|
|
Yes
|
247/1,976
|
125.0 (109.9–141.6)
|
72/2,065
|
34.9 (27.3–43.9)
|
76/2,064
|
36.8 (29.0–46.1)
|
|
No
|
115/467
|
246.4 (203.5–295.8)
|
32/498
|
64.2 (43.9–90.7)
|
29/501
|
57.9 (38.8–83.1)
|
|
Rate ratio (yes vs. no)d
|
–
|
0.5 (0.4–0.6)
|
–
|
0.5 (0.4–0.8)
|
–
|
0.6 (0.4–1.0)
|
|
By Primary site
|
|
Connective/subcutaneous
|
136/830
|
163.9 (137.5–193.8)
|
33/877
|
37.6 (25.9–52.8)
|
37/875
|
42.3 (29.8–58.3)
|
|
Digestive system
|
120/832
|
144.2 (119.5–172.4)
|
38/879
|
43.2 (30.6–59.4)
|
29/885
|
32.8 (22.0–47.1)
|
|
Other/unknowng
|
111/805
|
137.8 (113.3–165.9)
|
34/833
|
40.8 (28.3–57.0)
|
40/830
|
48.2 (34.4–65.7)
|
- Per SEER-Medicare data use agreement, cell sizes <11 cannot be displayed, nor can estimates that could be used to derive the undisplayed numbers <11. Rate ratios are highlighted in italics.
-
a
DVT deep vein thrombosis, PE pulmonary embolism, OTE other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd–Chiari syndrome, and venous embolism/thrombosis of renal vein.
-
b
N number of VTE events, P-Y person-years.
-
cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation (≥65 years) of STS patients. Only first VTE counted in rate estimates.
-
dRate ratios are unadjusted.
-
eHistory of VTE of interest in the 12 months before STS diagnosis.
-
fHistory of CVD is defined as a history of any of the following events in the 12 months before STS diagnosis: myocardial infarction, ischemic stroke, onset congestive heart failure, angina, or TIA.
-
gOther/unknown category includes primary sites of the breast, female genital system, other non-epithelial, respiratory system, urinary system, other sites and unknown sites.
